404 related articles for article (PubMed ID: 30476537)
1. Gadolinium tissue deposition in the periodontal ligament of mice with reduced renal function exposed to Gd-based contrast agents.
Delfino R; Biasotto M; Candido R; Altissimo M; Stebel M; Salomè M; van Elteren JT; Vogel Mikuš K; Zennaro C; Šala M; Addobbati R; Tromba G; Pascolo L
Toxicol Lett; 2019 Feb; 301():157-167. PubMed ID: 30476537
[TBL] [Abstract][Full Text] [Related]
2. Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS).
Sato T; Ito K; Tamada T; Kanki A; Watanabe S; Nishimura H; Tanimoto D; Higashi H; Yamamoto A
Magn Reson Imaging; 2013 Oct; 31(8):1412-7. PubMed ID: 23643157
[TBL] [Abstract][Full Text] [Related]
3. Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents.
Pietsch H; Lengsfeld P; Steger-Hartmann T; Löwe A; Frenzel T; Hütter J; Sieber MA
Invest Radiol; 2009 Apr; 44(4):226-33. PubMed ID: 19252439
[TBL] [Abstract][Full Text] [Related]
4. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
[TBL] [Abstract][Full Text] [Related]
5. NSF evaluation of gadolinium biodistribution in renally impaired rats: Using novel metabolic Gd2O3 nanoparticles coated with β-cyclodextrin (Gd2O3@PCD) in MR molecular imaging.
Ashouri H; Riyahi Alam N; Khoobi M; Haghgoo S; Rasouli Z; Gholami M
Magn Reson Imaging; 2024 Apr; 107():120-129. PubMed ID: 38215955
[TBL] [Abstract][Full Text] [Related]
6. The involvement of pro-inflammatory cytokines in nephrogenic systemic fibrosis - a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide.
Steger-Hartmann T; Raschke M; Riefke B; Pietsch H; Sieber MA; Walter J
Exp Toxicol Pathol; 2009 Nov; 61(6):537-52. PubMed ID: 19131226
[TBL] [Abstract][Full Text] [Related]
7. Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis--an autopsy-based review.
Sanyal S; Marckmann P; Scherer S; Abraham JL
Nephrol Dial Transplant; 2011 Nov; 26(11):3616-26. PubMed ID: 21441397
[TBL] [Abstract][Full Text] [Related]
8. Exposure of Macrophages to Low-Dose Gadolinium-Based Contrast Medium: Impact on Oxidative Stress and Cytokines Production.
Weng TI; Chen HJ; Lu CW; Ho YC; Wu JL; Liu SH; Hsiao JK
Contrast Media Mol Imaging; 2018; 2018():3535769. PubMed ID: 30627059
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium Retention in Erythrocytes and Leukocytes From Human and Murine Blood Upon Treatment With Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
Di Gregorio E; Furlan C; Atlante S; Stefania R; Gianolio E; Aime S
Invest Radiol; 2020 Jan; 55(1):30-37. PubMed ID: 31503081
[TBL] [Abstract][Full Text] [Related]
10. A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media.
Sieber MA; Pietsch H; Walter J; Haider W; Frenzel T; Weinmann HJ
Invest Radiol; 2008 Jan; 43(1):65-75. PubMed ID: 18097279
[TBL] [Abstract][Full Text] [Related]
11. Gadolinium Presence in the Brain After Administration of the Liver-Specific Gadolinium-Based Contrast Agent Gadoxetate: A Systematic Comparison to Multipurpose Agents in Rats.
Jost G; Frenzel T; Boyken J; Schoeckel L; Pietsch H
Invest Radiol; 2019 Aug; 54(8):468-474. PubMed ID: 30932931
[TBL] [Abstract][Full Text] [Related]
12. Quantification and Assessment of the Chemical Form of Residual Gadolinium in the Brain After Repeated Administration of Gadolinium-Based Contrast Agents: Comparative Study in Rats.
Frenzel T; Apte C; Jost G; Schöckel L; Lohrke J; Pietsch H
Invest Radiol; 2017 Jul; 52(7):396-404. PubMed ID: 28125438
[TBL] [Abstract][Full Text] [Related]
13. Increased Retention of Gadolinium in the Inflamed Brain After Repeated Administration of Gadopentetate Dimeglumine: A Proof-of-Concept Study in Mice Combining ICP-MS and Micro- and Nano-SR-XRF.
Wang S; Hesse B; Roman M; Stier D; Castillo-Michel H; Cotte M; Suuronen JP; Lagrange A; Radbruch H; Paul F; Taupitz M; Schellenberger E; Sack I; Infante-Duarte C
Invest Radiol; 2019 Oct; 54(10):617-626. PubMed ID: 31033673
[TBL] [Abstract][Full Text] [Related]
14. Effects of gadolinium contrast agents in naïve and nephrectomized rats: relevance to nephrogenic systemic fibrosis.
Grant D; Johnsen H; Juelsrud A; Løvhaug D
Acta Radiol; 2009 Mar; 50(2):156-69. PubMed ID: 19160079
[TBL] [Abstract][Full Text] [Related]
15. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
16. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue.
Wiginton CD; Kelly B; Oto A; Jesse M; Aristimuno P; Ernst R; Chaljub G
AJR Am J Roentgenol; 2008 Apr; 190(4):1060-8. PubMed ID: 18356456
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis of nephrogenic systemic fibrosis by means of elemental bioimaging and speciation analysis.
Birka M; Wentker KS; Lusmöller E; Arheilger B; Wehe CA; Sperling M; Stadler R; Karst U
Anal Chem; 2015 Mar; 87(6):3321-8. PubMed ID: 25708271
[TBL] [Abstract][Full Text] [Related]
18. The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis.
Prybylski JP; Jay M
Adv Chronic Kidney Dis; 2017 May; 24(3):176-182. PubMed ID: 28501081
[TBL] [Abstract][Full Text] [Related]
19. Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions.
Sieber MA; Lengsfeld P; Frenzel T; Golfier S; Schmitt-Willich H; Siegmund F; Walter J; Weinmann HJ; Pietsch H
Eur Radiol; 2008 Oct; 18(10):2164-73. PubMed ID: 18545998
[TBL] [Abstract][Full Text] [Related]
20. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy.
High WA; Ranville JF; Brown M; Punshon T; Lanzirotti A; Jackson BP
J Am Acad Dermatol; 2010 Jan; 62(1):38-44. PubMed ID: 19896750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
